WO2021138325A1 - Compositions et procédés pour la détection du bunyavirus - Google Patents

Compositions et procédés pour la détection du bunyavirus Download PDF

Info

Publication number
WO2021138325A1
WO2021138325A1 PCT/US2020/067314 US2020067314W WO2021138325A1 WO 2021138325 A1 WO2021138325 A1 WO 2021138325A1 US 2020067314 W US2020067314 W US 2020067314W WO 2021138325 A1 WO2021138325 A1 WO 2021138325A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
sequence
probe
sequence identity
complement
Prior art date
Application number
PCT/US2020/067314
Other languages
English (en)
Inventor
Michael G. BERG
Todd V. MEYER
Mary A. RODGERS
Gavin A. Cloherty
Ka-Cheung Luk
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of WO2021138325A1 publication Critical patent/WO2021138325A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes

Definitions

  • compositions, methods, and kits for amplifying and detecting human bunyavimses are provided herein.
  • bunyavirus specific nucleic acid probes and primers are provided herein, and methods for detecting bunyavirus nucleic acid.
  • Bunyavimses are enveloped viruses with three linear segments comprised of negative sense, single stranded RNA. Rodents often serve as reservoirs, and mosquitoes and ticks as vectors, with humans occasionally accidental hosts. They can infect the human central nervous system, various organs and vascular endothelium and often cause encephalitis and fever. Accordingly, what is needed are compositions, methods, and kits for diagnosing bunyavirus infection in a subject.
  • primers for detecting bunyavirus in a sample comprises a sequence with 80% or more sequence identity to 8EQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 8, or complements thereof.
  • probes for detecting bunyavirus in a sample comprising a sequence with 80% or more sequence identity to SEQ ID NO: 6, SEQ ID NO: 9, or complements thereof.
  • compositions for detecting hunyavirus in a sample in some embodiments, the composition comprises at least one forward primer comprising a sequence with 80% or more sequence identity to SEQ ID NO: 4 or a complement thereof and at least one reverse primer comprising a sequence with 80% or more sequence identity to SEQ ID NO: 5 or a complement thereof.
  • the composition comprises at least one forward primer comprising a sequence with 80% or more sequence identity to SEQ ID NO: 7 or a complement thereof and at least one reverse primer comprising a sequence with 80% or more sequence identity' to SEQ ID NO: 8 or a complement thereof.
  • the composition comprises at least one forward primer comprising a sequence with 80% or more sequence identity to SEQ ID NO: 4 or a complement thereof, at least one reverse primer comprising a sequence with 80% or more sequence identity to SEQ ID NO: 5 or a complement thereof, and a probe comprising a sequence with 80% or more sequence identity to SEQ ID NO: 6 or a complement thereof.
  • the composition at least one forward primer comprising a sequence with 80% or more sequence identity to SEQ ID NO: 7 or a complement thereof at least one reverse primer comprising a sequence with 80% or more sequence identity to SEQ ID NO: 8 or a complement thereof and a probe comprising a sequence with 80% or more sequence identity' to SEQ ID NO: 9 or a complement thereof.
  • the method comprises contacting the sample with at least one primer and/or at least one probe.
  • the hunyavirus comprises at least one sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3.
  • kits for amplifying and detecting hunyavirus in a sample comprise at least one forward primer comprising a sequence with 80% or more sequence identity to SEQ ID NO: 4 or a complement thereof at least one reverse primer comprising a sequence with 80% or more sequence identity to SEQ ID NO: 5 or a complement thereof, and a probe comprising a sequence with 80% or more sequence identity to SEQ ID NO: 6 or a complement thereof.
  • kits comprise at least one forward primer comprising a sequence with 80% or more sequence identity to SEQ ID NO: 7 or a complement thereof, at least one reverse primer comprising a sequence with 80% or more sequence identity to SEQ ID NO: 8 or a complement thereof, and a probe comprising a sequence with 80% or more sequence identity to SEQ ID NO: 9 or a complement thereof.
  • isolated polynucleotides having 50% or more sequence identity to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or fragments thereof
  • vectors and host cells comprising the same.
  • isolated polypeptides having 80% or more sequence identity to the polypeptide encoded by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or fragments thereof.
  • host cells comprising the same.
  • FIGS. 1A-1B show representative drawings of the structure of bunyaviruses.
  • FIG. 2, FIG. 3, and FIG. 4 show coverage plots for the various segments of the novel bunyavirus described herein. Multiple rounds of iterative mapping, contig assembly, and BLASTx verification were performed to arrive at the following draft genome. For each segment, the draft genome is shown with N's inserted for gaps. Raw' data was mapped back to the draft genome reference and depicted as a coverage plot. The coverage plot for segment L is shown in FIG. 2, for segment M is shown in FIG. 3, and for segment S is shown in FIG. 4.
  • FIG. 5 shows linearized RNA for the bunyavirus positive control developed by cloning the novel bunyavirus described herein into a pBluescript II XR predigested vector.
  • FIGS. 6A-6C show F AM signals of the amplification curves generated using the bunyavirus positive control and various primer/probe pairs.
  • FIGS. 7A-7C show FAM signals of the amplification curves generated using patient sample 594 compared to the positive control data shown in FIG. 6A-6C.
  • FIG, 8A-8B show the estimated number of log copies of virus per reaction for the positive control sample based upon the FAM signals using a linear regression model.
  • FIGS. 9A-9C show Cy5 signals of the amplification curves generated using the bunyavirus positive control and various primer/probe pairs.
  • FIGS. 10A-IOC show Cy5 signals of the amplification curves generated using patient sample 594 compared to the positive control data shown in FIG. 9A-9C.
  • FIG. 11 A-11 B show the estimated number of log copies of virus per reaction for the positive control sample based upon Cy5 signals using a linear regression model.
  • the present disclosure relates to materials and methods for amplification and detection of bunyavirus in a sample.
  • each intervening number there between with the same degree of precision is explicitly contemplated.
  • the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the number 6.0, 6.1, 6,2, 6.3, 6.4, 6,5, 6.6, 6.7, 6.8, 6.9, and 7.0 are explicitly contemplated.
  • the term “amphcon” refers to a nucleic acid generated via an amplification reaction.
  • the amplicon is typically double stranded DNA; however, it may be RNA and/or a DNA:RNA hybrid.
  • the amphcon comprises DNA complementary to a sample nucleic acid.
  • primer pairs are configured to generate ampl icons from a sample nucleic acid.
  • the base composition of any given amphcon may include the primer pair, the complement of the primer pair, and the region of a sample nucleic acid that was amplified to generate the amplicon.
  • the incorporation of the designed primer pair sequences into an amplicon may replace the native sequences at the primer binding site, and complement thereof, in certain embodiments, after amplification of the target region using the primers, the resultant amplicons having the primer sequences are used for subsequent analysis (e.g. base composition determination, for example, via direct sequencing).
  • the amplicon further comprises a length that is compatible with subsequent analysis.
  • An example of an amplicon is a DNA or an RNA product (usually a segment of a gene, DNA or RNA) produced as a result of PCR real-time PCR RT-PCR, competitive RT-PCR ligase chain reaction (LCR), gap LCR strand displacement amplification (SDA), nucleic acid sequence-based amplification (NASBA), transcription-mediated amplification (TMA), or the like.
  • LCR competitive RT-PCR ligase chain reaction
  • SDA gap LCR strand displacement amplification
  • NASBA nucleic acid sequence-based amplification
  • TMA transcription-mediated amplification
  • amplification As used herein, the phrases “amplification,” “amplification method,” or “amplification reaction,” are used interchangeably and refer to a method or process that increases the representation of a population of specific nucleic acid (all types of DNA or RNA) sequences (such as a target sequence or a target nucleic acid) in a sample.
  • amplification methods that can be used in the present disclosure include, but are not limited to, PCR real-time PCR, RT-PCR, competitive RT-PCR, and the like, all of which are known to one skilled in the art,
  • amplification conditions refers to conditions that promote annealing and/or extension of primer sequences. Such conditions are well-known in the art and depend on the amplification method selected.
  • PCR amplification conditions generally comprise thermal cycling, e.g., cycling of the reaction mixture between two or more temperatures. In isothermal amplification reactions, amplification occurs without thermal cycling although an initial temperature increase may be required to initiate the reaction.
  • Amplification conditions encompass all reaction conditions including, but not limited to, temperature and temperature cycling, buffer, salt, ionic strength, pH, and the like,
  • amplification reagents refers to reagents used in amplification reactions and may include, but is not limited to, buffers, reagents, enzymes having reverse transcriptase, and/or polymerase, or exonuclease activities; enzyme cofactors such as magnesium or manganese; salts; and deoxynucleotide triphosphates (ciNTPs), such as deoxyadenosine triphosphate (dATP), deoxyguanosine triphosphate (dGTP), deoxycytidine triphosphate (dCTP), deoxythymidine triphosphate (dTTP), and deoxyuridine triphosphate (dUTP).
  • ciNTPs deoxynucleotide triphosphates
  • Amplification reagents may readily be selected by one skilled in the art depending on the amplification method employ ed.
  • a “coding sequence” is a polynucleotide sequence which is transcribed into mRNA and translated into a polypeptide when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by and include a translation start codon at the 5'-terminus and one or more translation stop codons at the 3 '-terminus.
  • a coding sequence can include, but is not limited to, mRNA, cDNA, and recombinant polynucleotide sequences.
  • control sequence refers to polynucleotide sequences which are necessary to effect the expression of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism. In prokaryotes, such control sequences generally include promoter, ribosomal binding site and terminators: in eukaryotes, such control sequences generally include promoters, terminators and, in some instances, enhancers.
  • control sequence thus is intended to include at a minimum all components whose presence is necessary for expression, and also may include additional components whose presence is advantageous, for example, leader sequences.
  • a “conformational epitope” is an epitope that is comprised of specific juxtaposition of amino acids in an immunologically recognizable structure, such amino acids being present on the same polypeptide in a contiguous or non-contiguous order or present on different polypeptides.
  • the phrase, "directly detectable,” when used in reference to a detectable label or detectable moiety, means that the detectable label or detectable moiety does not require further reaction or manipulation to be detectable. For example, a fluorescent moiety is directly detectable by fluorescence spectroscopy methods.
  • the phrase "indirectly detectable,” when used herein in reference to a detectable label or detectable moiety, means that the detectable label or detectable moiety becomes detectable after further reaction or manipulation.
  • a hapten becomes detectable after reaction with an appropriate antibody attached to a reporter, such as a fluorescent dye.
  • Encoded by refers to a nucleic acid sequence winch codes for a polypeptide sequence. Also encompassed are polypeptide sequences winch are immunologically identifiable with a polypeptide encoded by the sequence.
  • a “polypeptide,” “protein,” or “amino acid” sequence as claimed herein may have at least 60% similarity, more preferably at least about 70% similarity, and most preferably about 80% similarity to a particular polypeptide or amino acid sequence specified below.
  • epitope means an antigenic determinant of a polypeptide.
  • an epitope can comprise three amino acids in a spatial conformation which is unique to the epitope.
  • an epitope consists of at least five such amino acids, and more usually, it consists of at least eight to ten amino acids.
  • Methods of examining spatial conformation include, for example, x-ray crystallography and two- dimensional nuclear magnetic resonance.
  • fluorophore fluorescent moiety
  • fluorescent label fluorescent dye
  • fluorescent dye refers to a molecule that absorbs a quantum of electromagnetic radiation at one wavelength, and emits one or more photons at a different, typically longer, wavelength in response thereto.
  • Numerous fluorescent dyes of a wide variety of structures and characteristics are suitable for use in the practice of the present disclosure. Methods and materials are known for fluorescently labeling nucleic acid molecules (See, R. P, Haugland, "Molecular Probes: Handbook of Fluorescent Probes and Research Chemicals 1992- 1994,” 5th Ed., 1994, Molecular Probes, Inc.).
  • a fluorescent label or moiety absorbs and emits light with high efficiency (e.g,, has a high molar absorption coefficient at the excitation wavelength used, and a high fluorescence quantum yield), and is photostable (e.g., does not undergo significant degradation upon light excitation within the time necessary to perform the analysis).
  • some fluorescent dyes transfer energy to another fluorescent dye in a process called fluorescence resonance energy transfer (FRET), and the second dye produces the detected signal.
  • FRET fluorescence resonance energy transfer
  • FRET fluorescent dye pairs are also encompassed by the term “fluorescent moiety.”
  • fluorescent moiety Such FRET fluorescent dye pairs are also encompassed by the term “fluorescent moiety.”
  • the use of physically- linked fluorescent reporters/quencher moieties is also within the scope of the present disclosure, in these aspects, when the fluorescent reporter and quencher moiety are held in close proximity, such as at the ends of a probe, the quencher moiety pre vents detection of a fluorescent signal from the reporter moiety. When the two moieties are physically separated, such as after cleavage by a DNA polymerase, the fluorescent signal from the reporter moiety becomes detectable.
  • a “fragment” of a specified polypeptide refers to an amino acid sequence which comprises at least about 3-5 amino acids, more preferably at least about 8-10 amino acids, and even more preferably at least about 15-20 amino acids, derived from the specified polypeptide.
  • a “fragment” of a specified polynucleotide refers to a nucleotide sequence which comprises at least 10 base pairs.
  • a fragment may comprise at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, or at least 100 base pairs.
  • hybridization refers to the formation of complexes between nucleic acid sequences which are sufficiently complementary' to form complexes via Watson- Crick base pairing or non-canonicai base pairing.
  • a primer ''hybridizes with a target sequence (template)
  • a target sequence template
  • such complexes or hybrids
  • hybridizing sequences need not have perfect complementarity to provide stable hybrids. In many situations, stable hybrids will form where fewer than about 10% of the bases are mismatches.
  • the term "complementary” refers to an oligonucleotide that forms a stable duplex with its complement under assay conditions, generally where there is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94% about 95%, about 96%, about 97%, about 98%, or about 99% greater homology.
  • Those skilled in the art understand how to estimate and adjust the stringency of hybridization conditions such that sequences having at least a desired level of complementarity will stably hybridize, while those having lower complementarity will not.
  • immunologically identifiable with/as refers to the presence of epitope(s) and polypeptide(s) which also are present in and are unique to the designated polypeptide(s). Immunological identity may be determined by antibody binding and/or competition in binding. These techniques are known to the skilled artisan and also are described herein. The uniqueness of an epitope also can be determined by computer searches of known data banks, such as GenBank, for the polynucleotide sequences which encode the epitope, and by amino acid sequence comparisons with other known proteins.
  • a polypeptide is “immunologically reactive” with an antibody when it binds to an antibody due to antibody recognition of a specific epitope contained within the polypeptide. Immunological reactivity may be determined by antibody binding, more particularly by the kinetics of antibody binding, and/or by competition in binding using as competitor(s) a known polypeptide(s) containing an epitope against which the antibody is directed. The methods for determining whether a polypeptide is immunologically reactive with an antibody are known in the art.
  • isolated means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring).
  • a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or DNA or polypeptide, which is separated from some or all of the coexisting materials in the natural system, is isolated.
  • Such polynucleotide could be part of a vector and/or such polynucleotide or polypeptide could be part of a composition, and still be isolated in that the vector or composition is not part of its natural environment.
  • labeling and labeled with a detectable label are used interchangeably herein and specify that an entity (e.g., a primer or a probe) can be visualized, for example following binding to another entity (e.g, an amplification product or amplicon).
  • entity e.g., a primer or a probe
  • the detectable label is selected such that it generates a signal which can be measured and whose intensity is related to (e.g., proportional to) the amount of bound entity.
  • a wide variety of systems for labeling and/or detecting nucleic acid molecules, such as primer and probes are well-known in the art.
  • Labeled nucleic acids can be prepared by incorporation of, or conjugation to, a label that is directly or indirectly detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical, chemical, or other means.
  • Suitable detectable agents include, but are not limited to, radionuclides, fluorophores, chemiluminescent agents, microparticles, enzymes, colorimetric labels, magnetic labels, haptens, Molecular Beacons, aptamer beacons, and the like.
  • nucleic acid refers to at least two nucleotides covalently linked together.
  • the depiction of a single strand also defines the sequence of the complementary strand.
  • an oligonucleotide also encompasses the complementary strand of a depicted single strand.
  • An oligonucleotide also encompasses substantially identical nucleic acids and complements thereof. Oligonucleotides can be single-stranded or double-stranded, or can contain portions of both double-stranded and single-stranded sequences.
  • the oligonucleotide can be DNA, both genomic and complimentary DNA (cDNA), RNA, or a hybrid, where the nucleic acid can contain combinations of deoxyribo- and ribonucleotides, and combinations of bases including uracil, adenine, thymine, cytosine, guanine, mosine, xanthine hypoxanthine, isocytosine and isoguanme. Oligonucleotides can be obtained by chemical synthesis methods or by recombinant methods.
  • a particular oligonucleotide sequence can encompass conservatively modified variants thereof (e.g., codon substitutions), alleles, orthologs, single nucleotide polymorphisms (SNPs), and complementary sequences as well as the sequence explicitly indicated.
  • conservatively modified variants thereof e.g., codon substitutions
  • alleles e.g., alleles
  • orthologs e.g., single nucleotide polymorphisms (SNPs)
  • SNPs single nucleotide polymorphisms
  • “Operably linked” refers to a situation wherein the components described are in a relationship permitting them to function in their intended manner.
  • a control sequence “operably linked” to a coding sequence is ligated in such a manner that expression of the coding sequence is achieved under conditions compatible with the control sequences.
  • Polypeptide and “protein” are used interchangeably herein and indicate a molecular chain of amino acids linked through covalent and/or nonco valent bonds. The terms do not refer to a specific length of the product. Thus, peptides, oligopeptides and proteins are included within the definition of polypeptide. The terms include post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like. In addition, protein fragments, analogs, mutated or variant proteins, fusion proteins and the like are included within the meaning of polypeptide.
  • oligonucleotide primer refers to an oligonucleotide capable of acting as a point of initiation for DNA synthesis under suitable conditions. Suitable conditions include those in which hybridization of the oligonucleotide to a template nucleic acid occurs, and synthesis or amplification of the target sequence occurs, in the presence of four different nucleoside triphosphates and an agent for extension (e.g., a DNA polymerase) in an appropriate buffer and at a suitable temperature.
  • agent for extension e.g., a DNA polymerase
  • the phrase "forward primer” refers to a primer that hybridizes (or anneals) with the target sequence (e.g., template strand).
  • reverse primer refers to a primer that hybridizes (or anneals) to the complementary strand of the target sequence.
  • the forward primer hybridizes with the target sequence 5' with respect to the reverse primer.
  • forward primer refers to a primer that hybridizes (or anneals) with the target sequence (e.g., template strand).
  • reverse primer refers to a primer that hybridizes (or anneals) to the complementary strand of the target sequence. The forward primer hybridizes with the target sequence 5' with respect to the reverse primer.
  • the phrase "primer set” refers to two or more primers which together are capable of priming the amplification of a target sequence or target nucleic acid of interest (e.g., a target sequence within the bunyavirus).
  • the term “primer set” refers to a pair of primers including a 5' (upstream) primer (or forw3 ⁇ 4rd primer) that hybridizes with the 5 '-end of the target sequence or target nucleic acid to be amplified and a 3'
  • downstream primer or reverse primer
  • primer sets or primer pairs are particularly useful in PCR amplification reactions.
  • probe or “oligonucleotide primer” as used interchangeably herein refers to an oligonucleotide that hybridizes specifically to a target sequence in a nucleic acid, preferably in an amplified nucleic acid, under conditions that promote hybridization, to form a detectable hybrid.
  • a probe may contain a detectable moiety (e.g., a label) which either may be atached to the end(s) of the probe or may be internal.
  • the nucleotides of the probe which hybridize to the target nucleic acid sequence need not he strictly contiguous, as may be the case with a detectable moiety internal to the sequence of the probe.
  • Detection may either be direct (i.e., resulting from a probe hybridizing directly to the target sequence or amplified nucleic acid) or indirect (i.e., resulting from a probe hybridizing to an intermediate molecular structure that links the probe to the target sequence or amplified nucleic acid).
  • An oligonucleotide probe may comprise target- specific sequences and other sequences that contribute to three-dimensional conformation of the probe (e.g., as described in, e.g., U.S. Pat. Nos. 5,118,801 and 5,312,728).
  • primer and probe set refers to a combination including two or more primers which together are capable of priming the amplification of a target sequence or target nucleic acid, and least one probe which can detect the target sequence or target nucleic acid.
  • the probe generally hybridizes to a strand of an amplification product (or amplicon) to form an amplification product/probe hybrid, which can be detected using routine techniques known to those skilled in the art.
  • “Purified polypeptide” or “purified polynucleotide” refers to a polypeptide or polynucleotide of interest or fragment thereof which contains less than about 50%, preferably less than about 70%, and more preferably, less than about 90% of cellular components with which the polypeptide or polynucleotide of interest or fragment thereof is naturally associated. Methods for purifying are known in the art.
  • recombinant polypeptide or “recombinant protein”, used interchangeably herein, describe a polypeptide which by virtue of its origin or manipulation is not associated with all or a portion of the polypeptide with which it is associated in nature and/or is linked to a polypeptide other than that to which it is linked in nature.
  • a recombinant or encoded polypeptide or protein is not necessarily translated from a designated nucleic acid sequence. It also may be generated in any manner, including chemical synthesis or expression of a recombinant expression system.
  • “Recombinant host cells,” “host cells,” “cells,” “cell lines,” “cell cultures,” and other such terms denoting microorganisms or higher eukaryotic cell lines cultured as unicellular entities refer to cells which can be, or have been, used as recipients for recombinant vector or other transferred DNA, and include the original progeny of the original cell which has been transfected.
  • replicon means any genetic element, such as a plasmid, a chromosome or a virus, that behaves as an autonomous unit of polynucleotide replication within a cell.
  • sample generally refers to a biological material being tested for and/or suspected of containing an analyte of interest, such as a bunyavirus sequence.
  • the sample may be derived from any biological source, such as, a cervical, vaginal or anal swab or brush, or a phy siological fluid including, but not limited to, whole blood, serum, plasma, interstitial fluid, saliva, ocular lens fluid, cerebral spinal fluid, sweat, urine, milk, ascites fluid, mucus, nasal fluid, sputum, synovial fluid, peritoneal fluid, vaginal fluid, menses, aminotie fluid, semen, and so forth.
  • the sample may be used directly as obtained from the biological source or following a pretreatment to modify the character of the sample.
  • pretreatment may include preparing plasma from blood, diluting viscous fluids, and so forth. Methods of pretreatment may also involve filtration, precipitation, dilution, distillation, mixing, concentration, lyophilization, inactivation of interfering components, the addition of reagents, lysing, etc.
  • it may also be beneficial to modify a solid sample to form a liquid medium or to release the analyte.
  • the sample may be plasma.
  • sequence identity refers to the degree of similarity between two sequences (e.g., nucleic acid (e.g., oligonucleotide or polynucleotide sequences) or amino acid sequences).
  • sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes).
  • the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared.
  • the percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
  • Statistically significant refers to the likelihood that a relationship between two or more variables is caused by something other than random chance.
  • Statistical hypothesis testing is used to determine whether the result of a data set is statistically significant. In statistical hypothesis testing, a statistically significant result is attained whenever the observedp-value of a test statistic is less than the significance level defined of the study. The p-value is the probability of obtaining results at least as extreme as those observed, given that the null hypothesis is true. Examples of statistical hypothesis analysis include Wilcoxon signed-rank test, t-test, Chi-Square or Fisher's exact test. “Significant” as used herein refers to a change that has not been determined to be statistically significant (e.g., it may not have been subject to statistical hypothesis testing).
  • a mammal e.g., cow, pig, camel, llama, horse, goat, rabbit, sheep, hamsters, guinea pig, cat, dog, rat, and mouse
  • a non-human primate for example, a monkey, such as a cynomolgous or rhesus monkey, chimpanzee, etc.
  • the subject may be a human or a non-human.
  • the subject or patient may be undergoing other
  • synthetic peptide as used herein means a polymeric form of amino acids of any length, which may be chemically synthesized by methods well-known to those skilled in the art. These synthetic peptides are useful in various applications.
  • target sequence and “target nucleic acid” are used interchangeably herein and refer to that which the presence or absence of which is desired to be detected.
  • a target sequence preferably includes a nucleic acid sequence to which one or more primers will complex.
  • the target sequence can also include a probe- hybridizing region with which a probe will form a stable hybrid under appropriate amplification conditions.
  • a target sequence may be single-stranded or double-stranded.
  • transformation refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion. For example, direct uptake, transduction or f-mating are included.
  • the exogenous polynucleotide may be maintained as a non-integrated vector, for example, a plasmid, or alternatively, may be integrated into the host genome.
  • Treat,” “treating” or “treatment” are each used interchangeably herein to describe reversing, alleviating, or inhibiting the progress of a disease and/or injury, or one or more symptoms of such disease, to which such term applies.
  • the term also refers to preventing a disease, and includes preventing the onset of a disease, or preventing the symptoms associated with a disease.
  • a treatment may he either performed in an acute or chronic way.
  • the term also refers to reducing the severity of a disease or symptoms associated with such disease prior to affliction with the disease.
  • Such prevention or reduction of the seventy of a disease prior to affliction refers to administration of a pharmaceutical composition to a subject that is not at the time of administration afflicted with the disease. “Preventing” also refers to preventing the recurrence of a disease or of one or more symptoms associated with such disease. “Treatment” and “therapeutically,” refer to the act of treating, as “treating” is defined above. [0064] “Variant” is used herein to describe a peptide or polypeptide that differs in sequence by the insertion, deletion, or conservative substitution of amino acids, but retain at least one biological activity. Representative examples of “biological activity” include the ability to be bound by a specific antibody or to promote an immune response.
  • Variant is also used herein to describe a protein with a sequence that is substantially identical to a referenced protein with a sequence that retains at least one biological activity.
  • a conservative substitution of an amino acid i.e., replacing an amino acid with a different amino acid of similar properties (e.g., hydrophilicity, degree, and distribution of charged regions) is recognized in the art as typically involving a minor change. These minor changes can be identified, in part, by considering the hydropathic index of amino acids, as understood in the art. Kyte et al, J. Mol. Biol. 157:105-132 (1982). The hydropathic index of an amino acid is based on a consideration of its hydrophobicity and charge.
  • amino acids of similar hydropathic indexes can be substituted and still retain protein function.
  • amino acids having hydropathic indexes of ⁇ 2 are substituted.
  • the hydrophilicity of amino acids can also be used to reveal substitutions that would result in proteins retaining biological function.
  • a consideration of the hydrophilicity of amino acids in the context of a peptide permits calculation of the greatest local average hydrophilicity of that peptide, a useful measure that has been reported to correlate well with antigenicity and immunogenicity.
  • U.S. Patent No. 4,554,101 incorporated fully herein by reference.
  • Substitution of amino acids having similar hydrophilicity values can result in peptides retaining biological activity, for example immunogenicity, as is understood in the art.
  • Substitutions may be performed with amino acids having hydrophilicity values within ⁇ 2 of each other. Both the hydrophobicity index and the hydrophilicity value of amino acids are influenced by the particular side chain of that amino acid. Consistent with that observation, amino acid substitutions that are compatible with biological function are understood to depend on the relative similarity of the amino acids, and particularly the side chains of those amino acids, as revealed by the hydrophobicity, hydrophilicity, charge, size, and other properties. “Variant” also can be used to describe a poly peptide or a fragment thereof that has been differentially processed, such as by proteolysis, phosphorylation, or other post-translational modification, yet retains its antigen reactivity.
  • a “vector” is a replicon to which another polynucleotide segment is attached, such as to bring about the replication and/or expression of the attached segment.
  • scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. For example, any nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described herein are those that are well known and commonly used in the art. The meaning and scope of the terms should be clear; in the event, however of any latent ambiguity, definitions provided herein take precedent over any dictionary or extrinsic definition. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.
  • the present disclosure provides polynucleotide sequences derived from bunyavirus and polypeptides encoded thereby.
  • the polynucleotide(s) may be in the form of mRNA or DNA.
  • Polynucleotides in the form of DNA, cDNA, genomic DNA, and synthetic DNA are within the scope of the present disclosure.
  • the polynucleotide is in the form of DNA.
  • the polynucleotide is in the form of cDNA.
  • the polynucleotide is in the form of genomic DNA.
  • the polynucleotide is in the form of synthetic DNA.
  • the DNA may be double-stranded or single-stranded, and if single stranded may be the coding (sense) strand or non-coding (anti-sense) strand.
  • the coding sequence which encodes the polypeptide may be identical to the coding sequence provided herein or may be a different coding sequence which coding sequence, as a result of the redundancy or degeneracy of the genetic code, encodes the same polypeptide as the DNA provided herein,
  • the polynucleotides provided herein may include only the coding sequence for the polypeptide, or the coding sequence for the polypeptide and additional coding sequence such as a leader or secretory ' sequence or a proprotein sequence, or the coding sequence for the polypeptide (and optionally additional coding sequence) and non-coding sequence, such as a non-coding sequence 5' and/or 3' of the coding sequence for the polypeptide.
  • the disclosure includes variant polynucleotides containing modifications such as polynucleotide deletions, substitutions or additions, and any polypeptide modification resulting from the variant polynucleotide sequence.
  • a polynucleotide of the present disclosure also may have a coding sequence which is a naturally-occurring variant of the coding sequence provided herein.
  • the coding sequence for the polypeptide may be fused in the same reading frame to a polynucleotide sequence winch aids in expression and secretion of a polypeptide from a host cell, for example, a leader sequence which functions as a secretory sequence for controlling transport of a polypeptide from the cell.
  • the polypeptide having a leader sequence is a preprotein and may have the leader sequence cleaved by the host cell to form the polypeptide.
  • the polynucleotides may also encode for a proprotein winch is the protein plus additional 5' amino acid residues.
  • a protein having a prosequence is a proprotein and may in some cases be an inactive form of the protein.
  • the polynucleotide of the present disclosure may encode for a protein, or for a protein having a prosequence or for a protein having both a presequence (leader sequence) and a prosequence.
  • the polynucleotides of the present disclosure may also have the coding sequence fused in frame to a marker sequence winch allows for purification of the polypeptide of the present disclosure.
  • the marker sequence may be a hexa-histidine tag supplied by a pQE-9 vector to provide for purification of the polypeptide fused to the marker in the case of a bacterial host, or, for example, the marker sequence may he a hemagglutinin (HA) tag when a mammalian host e.g. COS-7 cells, is used.
  • the HA tag corresponds to an epitope derived from the influenza hemagglutinin protein. See, for example, I. Wilson et at, Cell 37:767 (1984).
  • segment L is provided in SEQ ID NO: 1.
  • isolated polynucleotides having 50% or more sequence identity e.g. at least 50%, 55%, 60%, 65%, 70%, 75%, 80%,
  • segment M is provided in SEQ ID NO: 2,
  • isolated polynucleotides having 50% or more sequence identity e.g. at least 50%, 55%, 60%, 65%, 70%, 75%, 80%,
  • segment S is provided in SEQ ID NO: 3.
  • isolated polynucleotides having 50% or more sequence identity e.g. at least 50%, 55%, 60%, 65%, 70%, 75%, 80%,
  • the present disclosure further relates to bunyavirus polypeptides.
  • the polypeptides may be encoded by any one of the polynucleotides provided herein.
  • the poly peptides may have the deduced amino acid sequence as provided herein, as well as fragments, analogs and derivatives of such polypeptides.
  • the polypeptides of the present disclosure may be recombinant polypeptides, natural purified polypeptides or synthetic polypeptides.
  • the fragment, derivative or analog of such a polypeptide may be one in which one or more of the amino acid residues is substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code; or it may be one in which one or more of the amino acid residues includes a substituent group; or it may be one in which the polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol); or it may be one in which the additional amino acids are fused to the polypeptide, such as a leader or secretory sequence or a sequence which is employed for purification of the polypeptide or a proprotein sequence.
  • Such fragments, derivatives and analogs are within the scope of the present disclosure.
  • the polypeptides and polynucleotides of the present disclosure are provided in an isolated form, are purified or are in isolated form and purified.
  • a polypeptide of the present disclosure may have an amino acid sequence that is identical to that of the naturally-occurring polypeptide or that is different by minor variations due to one or more amino acid substitutions.
  • the variation may be a “conservative change” typically in the range of about 1 to 5 amino acids, wherein the substituted amino acid has similar structural or chemical properties, e.g., replacement of leucine with isoleucine or threonine with serine.
  • variations may include nonconservative changes, e.g., replacement of a glycine with a tryptophan.
  • Similar minor variations may also include amino acid deletions or insertions, or both.
  • polypeptides having an amino acid sequence with 80% or more sequence identity e.g. at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%
  • SEQ iD NO: 1 or a fragment thereof e.g. at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%
  • isolated polypeptides having 80% or more sequence identity (e.g. at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to the polypeptide encoded by SEQ iD NO: 2 or a fragment thereof.
  • isolated polypeptides having 80% or more sequence identity (e.g. at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to the polypeptide encoded by SEQ ID NO: 3 or a fragment thereof.
  • vectors comprising a polynucleotide as disclosed herein. Any suitable vector may be used so long as it is replicable and viable in a host.
  • vectors comprising a polynucleotide having at least 50% sequence identity (e.g. 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or fragments thereof.
  • the polynucleotides of the present disclosure may be included in any one of a variety of expression vehicles, in particular vectors or plasmids for expressing a polypeptide.
  • the vector further comprises one or more regulatory sequences, such as a promoter.
  • the promoter may be operably linked to the polynucleotide sequence.
  • Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers.
  • CAT chloramphenicol transferase
  • Two appropriate vectors are pKK232-8 and pCM7.
  • Particular named bacterial promoters include lad, lacZ, T3, SP6, T7, gpt, lambda P sub R, P sub L and trp.
  • Eukaryotic promoters include cytomegalovirus (CMV) immediate early, herpes simplex virus (HSV) thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.
  • CMV cytomegalovirus
  • HSV herpes simplex virus
  • thymidine kinase early and late SV40
  • LTRs early and late SV40
  • LTRs early and late SV40
  • retrovirus early and late SV40
  • mouse metallothionein-I mouse metallothionein-I
  • vectors will include origins of replication and selectable markers permitting transformation of a host cell, e.g., the ampieillin resistance gene of E. coli and the S, cerevisiae TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence.
  • promoters can be derived from operons encoding glycolytic enzymes such as 3 -phosphoglycerate kinase (PGK), alpha factor, acid phosphatase, or heat shock proteins, among others.
  • the heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium.
  • the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.
  • Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter.
  • the vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host.
  • Suitable prokaryotic hosts for transformation include E. coli, Bacillus subtilis, Salmonella typhimurium and various species within the genera Pseudomonas, Streptomyces, and Staphylococcus, although others may also be employed as a routine mater of choice.
  • Useful expression vectors for bacterial use comprise a selectable marker and bacterial origin of replication derived from plasmids comprising genetic elements of the well-known cloning vector pBR322 (ATCC 37017).
  • Other vectors include but are not limited to PKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM1 (Promega Biotec, Madison, Wis.). These pBR322 “backbone” sections are combined with an appropriate promoter and the structural sequence to be expressed.
  • Such vectors include chromosomal nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; yeast plasmids, vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies.
  • chromosomal nonchromosomal and synthetic DNA sequences e.g., derivatives of SV40; bacterial plasmids; phage DNA; yeast plasmids, vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies.
  • the following vectors are provided by way of example.
  • Bacterial pINCY (Incyte Pharmaceuticals Inc., Palo Alto, Calif), pSPORTl (Life Technologies, Gaithersburg, Md.), pQE70, pQE60, pQE-9 (Qiagen) pBs, phagescript, psiX174, pBluescript SK, pBsKS, pNH8a, pNH16a, pNTI18a, pNH46a (Stratagene); pTrc99A, pKK223-3, pKK2330-3, pDR540, pRIT5 (Pharmacia).
  • Eukaryotic pWLneo, pSV2cat, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia).
  • the vector is a mammalian vector.
  • Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, 5' flanking nontranscribed sequences, and selectable markers such as the neomycin phosphotransferase gene.
  • DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early promoter, enhancer, splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements.
  • useful vectors include pRc/CMV and pcDNA3 (available from Invitrogen, San Diego, Calif.).
  • the desired polynucleotide may be inserted into the vector by a variety of procedures. In general, the polynucleotide is inserted into appropriate restriction endonuclease sites by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.
  • the polynucleotide in the expression vector may be operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis.
  • the expression vector may also contain a ribosome binding site for translation initiation and a transcription terminator.
  • the vector may also include appropriate sequences for amplifying expression.
  • the expression vectors preferably contain a gene to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillm resistance in E. coli.
  • Transcription may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that acts on a promoter increase its transcription.
  • Examples include the SV40 enhancer on the late side of the replication origin (bp 100 to 270), a cytomegalovirus early promoter enhancer, a polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.
  • host cells comprising a polynucleotide or a polypeptide as described herein.
  • host cells comprising a vector as described herein.
  • host cells that have been transformed with a vector comprising a polynucleotide having at least 50% sequence identity (e.g. 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or fragments thereof.
  • the vector containing the appropriate polynucleotide sequence, as well as an appropriate promoter or control sequences, may he employed to transform an appropriate host to permit the host to express a polypeptide as described herein.
  • host cells comprising a polypeptide as described herein.
  • host cells expressing a polypeptide having at least 80% sequence identity (e.g. 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to the polypeptide sequence encoded by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or fragments thereof.
  • the host cell used herein can be a higher eukaryotic ceil, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell.
  • Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (L. Davis et al., “Basic Methods in Molecular Biology”, 2nd edition, Appleton and Lang, Paramount Publishing, East Norwalk, Conn. [1994]).
  • bacterial cells such as A.
  • the host cells is a mammalian host cell.
  • Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts described by Gluzman, Cell 23:175 (1981), and other ceil lines capable of expressing a compatible vector, such as the Cl 27, 3T3, CHO, HeLa and BHK cell lines. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings provided herein.
  • the vectors in host cells can be used in a conventional manner to produce the gene product encoded by the polynucleotide sequence.
  • the polypeptides of the disclosure can be synthetically produced by conventional peptide synthesizers.
  • Polypeptides can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters.
  • Cell-free translation systems also can be employed to produce such proteins using RNAs derived from the DNA constructs of the present disclosure.
  • Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook et al, Molecular Cloning: A Laboratory Manual, Second Edition, (Cold Spring Harbor, N.Y., 1989), which is hereby incorporated by reference.
  • the selected promoter is derepressed by appropriate means (e.g., temperature shift or chemical induction), and cells are cultured for an additional period.
  • Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.
  • Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents; such methods are well-known to the ordinary- artisan.
  • the bunyavirus-derived polypeptides may be recovered and purified from ceil cultures by known methods including aminonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphoceliulose chromatography, hydrophobic interaction chromatography, hydroxyapatite chromatography or lectin chromatography. It is preferred to have low concentrations (approximately 0.1-5 mM) of calcium ion present during purification (Price et al., J Biol Chem. 244:917 [1969]). Protein refolding steps can be used, as necessary, in completing configuration of the protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.
  • HPLC high performance liquid chromatography
  • the polypeptides of the present disclosure may be natural ly purified products expressed from a high expressing cell line, or a product of chemical synthetic procedures, or produced by recombinant techniques from a prokaryotic or eukaryotic host (for example, by bacterial, yeast, higher plant, insect and mammalian cells in culture). Depending upon the host employed in a recombinant production procedure, the polypeptides of the present disclosure may be glycosylated with mammalian or other eukaryotic carbohydrates or may be non-glycosylated. The polypeptides of the disclosure may also include an initial methionine amino acid residue. [0097] The present disclosure further includes modified versions of the polypeptides described herein, such polypeptides comprising inactivated glycosylation sites, removal of sequences such as cysteine residues, removal of the site for proteolytic processing, and the like.
  • primers, probes, and compositions comprising the same for amplifying and detecting bunyavirus in a subject.
  • primers for amplifying bunyavirus in a sample are any suitable primer derived from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or fragments thereof.
  • the primer is any suitable primer that is a complement derived from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:
  • the primer has 80% or more sequence identity to the sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 8, or complements thereof.
  • the primer may have 80%, 85%, 90%, 91%, 92%., 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the primer of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 8, or complements thereof.
  • the primer is labeled with a detectable label.
  • One or more primers may be labeled with at least one detectable label.
  • the primer has a sequence of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 8, or complements thereof. In some embodiments, the primer has a sequence of SEQ ID NO: 4 or a complement thereof. In some embodiments, the primer has a sequence of SEQ ID NO: 5 or a complement thereof. In some embodiments, the primer has a sequence of SEQ ID NO: 7 or a complement thereof. In some embodiments, the primer has a sequence of SEQ ID NO: 8 or a complement thereof. In some embodiments, the primer is labeled with a detectable label. One or more primers may be labeled with at least one detectable label.
  • probes for detecting bunyavirus in a sample are any suitable probe derived from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or fragments thereof. In some embodiments, the probe is any suitable probe that is a complement derived from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or fragments thereof. In some embodiments, provided herein is a probe for detecting bunyavirus in a sample, the probe has a sequence having 80% or more sequence identity to a sequence of SEQ ID NO: 6, SEQ ID NO: 9, or complements thereof.
  • the probe may have 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 6, SEQ ID NO: 9, or complements thereof.
  • the probe has a sequence of SEQ ID NO: 6, SEQ ID NO: 9, or a complement thereof.
  • the probe may have a sequence of SEQ ID NO: 6 or a complement thereof.
  • the probe may have a sequence of SEQ ID NO: 9 or a complement thereof
  • the probe is labeled with a detectable label.
  • one or more probes are labeled with a detectable label.
  • compositions for amplifying bunyavirus m a sample may comprise any two or more primers as disclosed herein (e.g. a primer set).
  • the composition comprises at least one forward primer and at least one reverse primer having a sequence (i) derived from SEQ ID NO: 1, SEQ ID NO:
  • the composition comprises at least one forward primer having a sequence with at least 80% sequence identity (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 93%, 95%, 96%, 97%, 98%, 99%, or 100%) to the sequence of SEQ ID NO: 4 or a complement thereof, and at least one reverse primer having a sequence with at least 80% sequence identity (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 93%, 95%, 96%, 97%, 98%, 99%, or 100%) to SEQ ID NO: 5 or a complement thereof.
  • the composition comprises at least one forward primer having a sequence with at least 80% sequence identity (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 93%, 93%, 93%, 95%, 96%, 97%, 98%, 99%, or 100%) to SEQ ID NO: 5 or a complement thereof.
  • the composition comprises at least one forward primer having a sequence with at least
  • any or all of the at least one forward primer and at least one reverse primer can be labeled with at least one detectable label
  • the composition further comprises at least one probe.
  • the composition may further comprise any probe described herein.
  • the composition further comprises at least one probe (i) derived from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or fragments thereof; or (li) that is a complement derived from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or fragments thereof.
  • the composition further comprises a probe having a sequence with at least 80% sequence identity (e.g., 80%,
  • the composition further comprises a probe having a sequence with at least 80% sequence identity (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 93%, 95%, 96%, 97%, 98%, 99%, or 100%) to SEQ ID NO: 9 or a complement thereof.
  • the at least one probe can be labeled with at least one detectable label.
  • compositions for amplifying and detecting bunyavifus in a sample may comprise any suitable combination of primers and probes described herein (e.g. a primer and probe set).
  • the composition comprises at least one forward primer, at least one reverse primer and at least one probe (i) derived from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or fragments thereof; or (ii) that is a complement derived from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or fragments thereof.
  • the composition comprises at least one forward primer having a sequence with at least 80% sequence identity (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 93%, 95%, 96%, 97%, 98%, 99%, or 100%) to SEQ ID NO: 4 or a complement thereof, at least one reverse primer having a sequence with at least 80% sequence identity (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 93%, 95%, 96%, 97%, 98%, 99%, or 100%) to SEQ ID NO: 5 or a complement thereof, and a probe having a sequence with at least 80% sequence identity (e.g., 80%, 85%,
  • the composition may comprise a forward primer having the sequence of SEQ ID NO: 4 or a complement thereof, the reverse primer having the sequence of SEQ ID NO: 5 or a complement thereof, and the probe having the sequence of SEQ ID NO: 6 or a complement thereof.
  • a forward primer having the sequence of SEQ ID NO: 4 or a complement thereof
  • the reverse primer having the sequence of SEQ ID NO: 5 or a complement thereof
  • the probe having the sequence of SEQ ID NO: 6 or a complement thereof.
  • Such a composition would be useful for detecting the L segment/RdRp of a bunyavirus. Any or all of the primers and/or probes described herein can be labeled with one or more detectable labels.
  • the composition comprises at least one forward primer having a sequence with at least 80% sequence identity (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 93%, 95%, 96%, 97%, 98%, 99%, or 100%) to SEQ ID NO: 7 or a complement thereof, at least one reverse primer having a sequence with at least 80% sequence identity (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 93%, 95%, 96%, 97%, 98%, 99%, or 100%) to SEQ ID NO: 8 or a complement thereof, and a probe having a sequence with at least 80% sequence identity (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 93%, 95%, 96%, 97%, 98%, 99%, or 100%) to SEQ ID NO: 9 or a complement thereof
  • the composition may comprise a forward primer having the sequence of SEQ ID NO: 7 or a complement thereof
  • oligonucleotide analogues can be prepared based on the primers and probes of the present disclosure.
  • Such analogues may contain alternative structures such as peptide nucleic acids or "PNAs" (e.g., molecules with a peptide-like backbone instead of the phosphate sugar backbone of naturally occurring nucleic acids) and the like. These alternative structures are also encompassed by the primers and probes of the present disclosure.
  • PNAs peptide nucleic acids
  • the primers and probes of the present disclosure may contain deletions, additions and/or substitutions of nucleic acid bases, to the extent that such alterations do not negati vely affect the properties of these sequences.
  • the primers and probes of the present disclosure may be prepared by any of a variety of methods known in the art (See, for example, Sambrook et al, "Molecular Cloning. A Laboratory Manual," 1989, 2. Supp. Ed., Cold Spring Harbour Laboratory' Press: New York, NY; “PCR Protocols. A Guide to Methods and Applications 1990, M. A. Innis (Ed.), Academic Press: New York, NY; P. Tijssen "Hybridization with Nucleic Acid Probes — Laboratory' Techniques in Biochemistry and Molecular Biology (Parts I and II),” 1993, Elsevier Science; “PCR Strategies,” 1995, M. A.
  • primers and probes described herein may be prepared by chemical synthesis and polymerization based on a template as described, for example, in Narang et al, Meth, Enzymol, 1979, 68: 90-98; Brown et al., Meth. Enzymol. , 1979, 68: 109-151 and Belousov et al., Nucleic Acids Res., 1997, 25: 3440-3444).
  • oligo synthesizers such as those commercially available from Perkin Elmer/ Applied Biosystems, Inc. (Foster City, CA), DuPont (Wilmington, DE) or Milligen (Bedford, MA).
  • the primers and probes of the present, disclosure may be custom made and ordered from a variety of commercial sources well-known in the art, including, for example, the Midland Certified Reagent Company (Midland, TX), ExpressGen, Inc. (Chicago, IL), Operon Technologies, Inc. (Huntsville, AL), BioSeareh Technologies, Inc. (Novato, CA), and many others.
  • primers and probes of the present disclosure may be earned out by any of a variety of methods well-known in the art. Purification of primers and probes can be performed either by native acrylamide gel electrophoresis, by anion-exchange HPLC as described, for example, by Pearson et al., J. Chrom., 1983, 255: 137- 149 or by reverse phase HPLC (See, McFarland et al, Nucleic Acids Res., 1979, 7: 1067-1080).
  • modified primers and probes may be prepared using any of several means known in the art.
  • modifications include methylation, substitution of one or more of the naturally occurring nucleotides with an analog, and internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoroamidates, carbamates, etc.), or charged linkages (e.g., phosphorothioates, phosphorodithi oates, etc).
  • Primers and probes may contain one or more additional covalently linked moieties, such as, for example, proteins (e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc), intercalators (e.g., acridine, psoralen, etc), chelators (e.g., to chelate metals, radioactive metals, oxidative metals, etc), and alkylators.
  • Primers and probes may also be derivatized by formation of a methyl or ethyl phosphotriester or an alkyl phosphoramidate linkage.
  • primers and/or probes of the present disclosure may be modified with a detectable label.
  • the primers and/or the probes may be labeled with a detectable label or moiety before being used in one or more amplification/detection methods.
  • one or more probes are labeled with a detectable label or moiety.
  • the role of a detectable label is to allow visualization and/or detection of amplified target sequences (e.g., amplicons).
  • the detectable label is selected such that it generates a signal which can be measured and whose intensity is related (e.g., proportionally) to the amount of amplification product in the test sample being analyzed.
  • labeled probes can be covalent or non-covalent.
  • labeled probes can be prepared by incorporation of, or conjugation to, a detectable moiety.
  • Labels can be attached directly to the nucleic acid sequence or indirectly (e.g., through a linker).
  • Linkers or spacer arms of various lengths are known in the art and are commercially available, and can be selected to reduce steric hindrance, or to confer other useful or desired properties to the resulting labeled molecules (See, for example, Mansfield et al., Mol. Cell. Probes, 1995, 9: 145-156).
  • oligonucleotides such as primers and/or probes
  • Reviews of labeling protocols and label detection techniques can be found in, for example, L. J. Kricka, Ann. Clin. Biochem., 2002, 39: 114-129; van Gijlswijk et al, Expert Rev. Mol. Diagn., 2001, 1 : 81-91; and Joos et al, J. Biotechnol 1994, 35: 135- 153.
  • Standard nucleic acid labeling methods include: incorporation of radioactive agents, direct attachments of fluorescent dyes (See, Smith et al., Nucl.
  • Suitable detectable labels include, but are not limited to, various ligands, radionuclides or radioisotopes (e.g., 32 P, 35 S, 3 H, 14 C, 125 1, 131 l and the like); fluorescent dyes; chemiluminescent agents (e.g., acridinium esters, stabilized dioxetanes, and the like); spectrally resolvable inorganic fluorescent semiconductor nanocrystals (e.g., quantum dots), metal nanoparticles (e.g., gold, silver, copper and platinum) or nanoclusters; enzymes (e.g., horseradish peroxidase, beta-galactosidase, luciferase, alkaline phosphatase); colorimetric labels (e.g., dyes, colloidal gold, and the like); magnetic labels (e.g., DynaheadsTM); and biotin and dioxigenin, or other haptens and proteins for antisera or
  • fluorescent labeling moieties of a wide variety of chemical structures and physical characteristics are suitable for use in the practice of this disclosure.
  • Suitable fluorescent dyes include, but are not limited to, Quasar® dyes available from Biosearch Technologies, Novato, CA), fluorescein and fluorescein dyes (e.g., fluorescein isothiocyanine (FITC), naphthofluorescein, 4',5' ⁇ dichloro-2',7' ⁇ dimethoxy ⁇ fluorescein, 6-carboxyfluoresceins (e.g., FAM), VIC, NED, carbocyanme, merocyanine, styryl dyes, oxonol dyes, phycoerythrin, erythrosin, eosin, rhodamine dyes (e.g., carboxytetramethylrhodamine or TAMRA, carboxyrhodamine 6G, earboxy-X-rhodam
  • fluorescent dyes examples include but are not limited to, fluorescent dyes, as well as labeling kits. Fluorescent dyes, as well as labeling kits, are commercially available from, for example, Amersham Biosciences, Inc. (Piscataway, N. J.), Molecular Probes Inc. (Eugene, OR), and New England Bioiabs Inc. (Beverly, MA).
  • some fluorescent groups transfer energy to another fluorescent group (acceptor) in a process of fluorescence resonance energy transfer (FRET), and the second group produces the detectable fluorescent signal.
  • the probe may, for example, become detectable when hybridized to an amplified target sequence.
  • FRET acceptor/donor pairs suitable for use in the present disclosure include, for example, fluorescein/tetramethylrhodamine, IAEDANS/F1TC, IAEDANS/5- (iodoacetomido)fluorescein, B-phycoerythrin/Cy-5, and EDANS/Dabcyl, among others,
  • FRET pairs also include the use of physically- linked fluorescent reporter/queneher pairs.
  • a detectable label and a quencher moiety may be individually attached to either the 5' end or the 3‘ end of a probe, therefore placing the detectable label and the quencher moiety at opposite ends of the probe, or apart from one another along the length of the probe.
  • the detectable label and quencher moiety are reversibly maintained within such proximity that the quencher blocks the detection of the detectable label.
  • the detectable label and quencher moiety are separated thus permitting detection of the detectable label under appropriate conditions.
  • Patent Nos. 5,846,726, 5,925,517, 6,277,581 and 6,235,504) is well- known to those skilled in the art.
  • products of the amplification reaction can he detected as they are formed in a "real-time” manner: amplification product/probe hybrids are formed and detected while the reaction mixture is under amplification conditions.
  • the PCR detection probes are
  • TaqMan® -like probes that are labeled at the 5 '-end with a fluorescent moiety and at the 3'- end with a quencher moiety or alternatively the fluorescent moiety and quencher moiety are in reverse order, or further they may be placed along the length of the sequence to provide adequate separation when the probe hybridizes to a target sequence to allow- satisfactory detection of the fluorescent moiety.
  • Suitable fluorophores and quenchers for use with TaqMan® -like probes are disclosed in U.S. Patent Nos. 5,210,015, 5,804,375, 5,487,792, and 6,214,979, and WO 01/86001.
  • quenchers include, but are not limited, to DABCYL (e.g., 4-(4'- dimethylaminophenylazo)-benzoic acid) succiniinidyl ester, diarylrhodamine carboxylic acid, succinimidyl ester (or QSY-7), and 4',5'-dmitrofluoreseein carboxylic acid, succinimidyl ester (or QSY-33) (all of which are available from Molecular Probes (which is part of Invitrogen, Carlsbad, CA)), quencher 1 (Ql; available from Epoch Biosciences, Bothell, WA), or "Black hole quenchers" BHQ-I, BHQ-2, and BHQ-3 (available from BioSeareh Technologies, Inc., Novato, CA).
  • DABCYL e.g., 4-(4'- dimethylaminophenylazo)-benzoic acid
  • succiniinidyl ester diarylrhodamine carboxylic acid
  • the PCR detection probes are TaqMan® -like probes that are labeled at the 5' end with FAM and at the 3' end with a Black Hole Quencher® or Black Hole Quencher® plus (Biosearch Technologies, Novato, CA).
  • a "tail" of normal or modified nucleotides can also be added to probes for detectability- purposes.
  • a second hybridization with nucleic acid complementary to the tail and containing one or more detectable labels allows visualization of the amplicon/probe hybrids.
  • the selection of a particular labeling technique may depend on the situation and may be governed by several factors, such as the ease and cost of the labeling method, spectral spacing between different detectable labels used, the quality of sample labeling desired, the effects of the detectable moiety on the hybridization reaction (e.g., on the rate and/or efficiency of the hybridization process), the nature of the amplification method used, the nature of the detection system, the nature and intensity of the signal generated by the detectable label, and the like.
  • kits for detecting bumyavirus in a sample comprising contacting the sample with at least one primer and/or at least one probe.
  • the methods are performed using PCR.
  • the methods are performed using fluorescence in-situ hybridization (FISH).
  • FISH fluorescence in-situ hybridization
  • the primer(s) and/or probe(s) may be suitable for PCR or FISH techniques.
  • the at least one primer and/or the at least one probe may be labeled with a detectable label.
  • the bunyavirus comprises the sequence of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or a combination thereof.
  • methods for detecting bunyavirus comprise contacting the sample with any suitable combination of primers and probes described herein.
  • the present disclosure provides methods for detecting the presence of bunyavirus in a test sample.
  • bunyavirus levels may be quantified.
  • bunyavirus levels may be quantified per test sample by comparing test sample detection values against standard curves, such as curves generated using serial dilutions of previously quantified suspensions of one or more bunyavirus sequences or other standardized bunyavirus profiles.
  • the method comprises contacting the sample with a composition comprising one or more primers and at least one probe as described herein.
  • the method may comprise contacting the sample with at least one forward primer, at least one reverse primer and at least one probe (i) derived from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or fragments thereof; or (ii) that is a complement derived from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or fragments thereof.
  • Any or all of the at least one forward primer, at least one reverse primer and at least one probe may be labeled with at least one detectable label.
  • the method may comprise contacting the sample with a composition suitable for detecting the L segment/RdRp of bunyavirus.
  • the method may comprise contacting the sample with a forward primer having 80% or more sequence identity (e.g. 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to SEQ ID NO: 4 or a complement thereof, a reverse primer having 80% or more (e.g.
  • the method may comprise contacting the sample with a primer and probe set suitable for detecting the S-segment/nucleocapsid of bunyavirus.
  • the method may comprise contacting the sample with a forward primer having 80% or more sequence identity ' (e.g. 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to SEQ ID NO: 7 or a complement thereof, a reverse primer having 80% or more sequence identity (e.g. 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to SEQ ID NO: 8 or a complement thereof, and a probe having 80% or more sequence identity (e.g.
  • the one or more primers and/or probe may comprise a detectable label.
  • methods for detecting bunyavirus in a sample comprise contacting the sample with at least one forward primer and at least one reverse primer under amplification conditions to generate a first target sequence, and detecting hybridization between the first target sequence and at least one probe as an indication of the presence of bunyavirus in the sample.
  • the amplification conditions may comprise submitting the sample to an amplification reaction carried out in the presence of suitable amplification reagents.
  • the amplification reaction comprises PCR, real-time PCR, or reverse-transcriptase PCR.
  • primers or primer sets of the present disclosure to amplify bunyavirus target sequences in test samples is not limited to any particular nucleic acid amplification technique or any particular modification thereof.
  • the primers and primer sets of the present disclosure can be employed in any of a variety of nucleic acid amplification methods that are known in the art (See, for example, Kimmel et al, Methods Enzymol., 1987, 152: 307-316; Sambrook et al., "Molecular Cloning. A Laboratory Manual” , 1989, 2.Supp. Ed., Cold Spring Harbour Laboratory Press: New York, NY; “ Short Protocols in Molecular Biology” , F. M. Ausubel (Ed.), 2002, 5. Supp.
  • Such nucleic acid amplification methods include, but are not limited to, the Polymerase Chain Reaction (PCR).
  • PCR is described in a number of references, such as, but not limited to, "PCR Protocols: A Guide to Methods and Applications” , M. A. Innis (Ed.), 1990, Academic Press: New York; “PCR Strategies", M. A. Innis (Ed.), 1995, Academic Press: New York; “Polymerase chain reaction: basic principles and automation in PCR. A Practical Approach” , McPherson et al.
  • PCR including, TaqMan® -based assays (See, Holland et al., Proc. Natl. Acad. Sci., 1991, 88: 7276-7280), and reverse transcriptase polymerase chain reaction (or RT-PCR, described in, for example, U.S. Patent Nos. 5,322,770 and 5,310,652) are also included.
  • PCR a pair of primers is added to a test sample obtained from a subject (and thus contacted with the test sample) in excess to hybridize to the complementary strands of the target nucleic acid.
  • the primers are each extended by a DNA polymerase using the target sequence as a template.
  • the extension products become targets themselves after dissociation (denaturation) from the original target strand.
  • New primers are then hybridized and extended by the polymerase, and the cycle is repeated to exponentially increase the number of amplicons.
  • DNA polymerases capable of producing primer extension products in PCR reactions include, but are not limited to, E.
  • thermostable DNA polymerases isolated from Thermus aquaticus (Taq), available from a variety of sources (e.g., Perkin Elmer, Waltham, MA),
  • RNA target sequences may be amplified by first reverse transcribing (RT) the rnRNA into cDNA, and then performing PCR (RT- PCR), as described above. Alternatively, a single enzyme may be used for both steps as described m U.S. Patent No. 5,322,770.
  • isothermal enzymatic amplification reactions can be employed to amplify bunyavirus sequences using primers and primer sets of the present disclosure (Andras et al., Mol. Biotechnol, 2001,
  • IMA Transcription-Mediated Amplification
  • TMA Transcription-Mediated Amplification
  • Giachetti et aL J. Clin. Microbiol, 2002, 40: 2408-2419
  • lJ.S. Patent No. 5,399,491 Self- Sustained Sequence Replication
  • 3 SR Self- Sustained Sequence Replication
  • NASBA Nucleic Acid Sequence Based Amplification
  • SDA Strand Displacement Amplification
  • the probes described herein are used to detect amplification products generated by the amplification reaction.
  • the probes described herein may be employed using a variety of well-known homogeneous or heterogeneous methodologies.
  • Homogeneous detection methods include, but are not limited to, the use of FRET labels that are attached to the probes and that emit a signal in the presence of the target sequence, Molecular Beacons (See, Tyagi et al,, Nature Biotechnol, 1996, 14: 303-308; Tyagi et al,
  • the probes of the present disclosure are used in a TaqMan® assay.
  • a TaqMan® assay analysis is performed in conjunction with thermal cycling by monitoring the generation of fluorescence signals.
  • the assay system has the capability of generating quantitative data allowing the determination of target copy numbers. For example, standard curves can be generated using serial dilutions of previously quantified suspensions of one or more bunyavirus sequences, against which unknown samples can be compared.
  • the TaqMan® assay is conveniently performed using, for example, AmpliTaq GoldTM DNA polymerase, which has endogenous 5' nuclease activity, to digest a probe labeled with both a fluorescent reporter dye and a quencher moiety, as described above.
  • Assay results are obtained by measuring changes in fluorescence that occur during the amplification cycle as the probe is digested, uncoupling the fluorescent and quencher moieties and causing an increase in the fluorescence signal that is proportional to the amplification of the target sequence.
  • HPA hybridization protection assays
  • the probes are labeled with acridimum ester (AE), a highly chemiluminescent molecule (See, Weeks et al, CHn. Chem., 1983, 29: 1474-1479; Berry et al., CHn. Chem., 1988, 34: 2087-2090), using a non-nucleotide-based linker arm chemistry (See, U.S. Patent Nos. 5,585,481 and 5,185,439).
  • AE acridimum ester
  • AE highly chemiluminescent molecule
  • Chemiluminescence is triggered by AE hydrolysis with alkaline hydrogen peroxide, which yields an excited N-methyl acridone that subsequently deactivates with emission of a photon.
  • AE hydrolysis is rapid.
  • the rate of AE hydrolysis is greatly reduced when the probe is bound to the target sequence.
  • Heterogeneous detection systems are also well-known in the art and generally employ a capture agent to separate amplified sequences from other materials in the reaction mixture.
  • Capture agents typically comprise a solid support material (e.g,, microtiter wells, beads, chips, and the like) coated with one or more specific binding sequences.
  • a binding sequence may be complementary to a tail sequence added to oligonucleotide probes of the disclosure.
  • a binding sequence may be complementary to a sequence of a capture oligonucleotide, itself comprising a sequence complementary to a tail sequence of a probe.
  • kits including materials and reagents useful for the detection of bunyavirus according to methods described herein.
  • the description of the primers, probes, and compositions herein are also applicable to those same aspects of the methods for detecting bunyavirus described herein.
  • the kits can be used by diagnostic laboratories, experimental laboratories, or practitioners.
  • the kits comprise at least one of the primer sets or primer and probe sets described in herein and optionally, amplification reagents. Each kit preferably comprises amplification reagents for a specific amplification method.
  • a kit adapted for use with NASBA preferably contains primers with an RNA polymerase promoter linked to the target binding sequence
  • a kit adapted for use with SDA preferably contains primers including a restriction endonuclease recognition site 5' to the target binding sequence.
  • the probes of the present disclosure can contain at least one fluorescent reporter moiety and at least one quencher moiety.
  • the kit comprises a forward primer, a reverse primer, a probe, and amplification reagents and instructions for amplifying and detecting bunyavirus in a sample.
  • the primers and/or probe may comprise a detectable label.
  • the kit comprises at least one forwnrd primer, at least one reverse primer and at least one probe (i) derived from 8EQ ID NO: 1, 8EQ ID NO: 2, 8EQ ID NO: 3, or fragments thereof: or (ii) that is a complement derived from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or fragments thereof.
  • the kit can contain one or more labels for labeling any of the at least one forward primer, at least one reverse primer and at least one probe.
  • the kit comprises a forward primer having 80% or more sequence identity (e.g. 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to 8EQ ID NO: 4 or a complement thereof, and a reverse primer having 80% or more (e.g. 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 5 or a complement thereof.
  • the kit may further comprise a probe having 80% or more sequence identity (e.g.
  • the kit can contain one or more labels for labeling any of the at least one forward primer, at least one reverse primer and at least one probe.
  • the kit comprises a forward primer having 80% or more sequence identity (e.g. 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to SEQ ID NO: 7 or a complement thereof, and a reverse primer having 80% or more sequence identity (e.g. 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) to SEQ ID NO: 8 or a complement thereof, in some embodiments, the kit further comprises a probe having 80% or more sequence identity (e.g.
  • the kit can contain one or more labels for labeling any of the at least one forward primer, at least one reverse primer and at least one probe.
  • Suitable amplification reagents additionally include, for example, one or more of: buffers, reagents, enzymes having reverse transcriptase and/or polymerase activity or exonuclease activity , enzyme cofactors such as magnesium or manganese; salts; deoxynucleotide triphosphates (dNTPs) suitable for carrying out the amplification reaction.
  • kits may further comprise one or more of: wash buffers, hybridization buffers, labeling buffers, detection means, and other reagents.
  • the buffers and/or reagents are preferably optimized for the particular amplification/detection technique for which the kit is intended.
  • kits may be provided with an internal control as a check on the amplification efficiency, to prevent occurrence of false negative test results due to failures in the amplification, to check on cell adequacy, sample extraction, etc.
  • An optimal internal control sequence is selected in such a way that it will not compete with the target nucleic acid sequence in the amplification reaction.
  • Kits may also contain reagents for the isolation of nucleic acids from test samples prior to amplification before nucleic acid extraction.
  • kits of the present disclosure may optionally comprise different containers (e.g., vial, ampoule, test tube, flask, or bottle) for each individual buffer and/or reagent.
  • Each component will generally be suitable as aliquoted m its respective container or provided in a concentrated form.
  • Other containers sui table for conducting certa in steps of the amplification/detection assay may also be provided.
  • the individual containers are preferably maintained in close confinement for commercial sale.
  • Kits may also comprise instructions for using the amplification reagents and primer sets or primer and probe described herein: for processing the test sample, extracting nucleic acid molecules, and/or performing the test; and for interpreting the results obtained as well as a notice in the form prescribed by a governmental agency.
  • Such instructions optionally may be in printed form or on CD, DVD, or other format of recorded media.
  • Sample 594 (CHRB 2017.06.15.13; lane 2 for NGS) was drawn at Centre Hospitalier Roi Baudouinler in Kinshasa from a participant whose age or gender were not recorded.
  • the sample tested negative for HIV and HCV by multiplex PCR and by HIV Combo, although it was HBsAg positive.
  • HBV was sequenced and classified as Genotype A, with a high viral load of 8.92 log copies/ml.
  • RAPsearch which predicts the presence of a divergent virus
  • the ‘viral in nr’ file had 26,379 hits to HBV (of 27,015 total; 98%), but it also had 566 hits to various bunyaviruses. [0152] Similarly, the ‘not in nr’ file had a number of bunyavirus hits which are enumerated below:
  • ARM2 hits were quantified and separated by taxonomic classifications. The list below contains the number of times the species is listed in a psiBLAST alignment iteration.
  • Bunyaviruses are enveloped and have three linear segments comprised of negative sense, single stranded RNA.
  • the L segment is about 6.9kb, M segment about 4.5kb and S segment about Ikb, which encode for six proteins. Almost all of the hits described herein were to the genus Orthobunyavirus, m the Peribunyaviridae family.
  • Genome Assembly, Percent Identity and Mapping The near complete genome was assembled. Multiple rounds of iterative mapping, contig assembly, and BLASTx verification were performed to arrive at the following draft genome. For each segment, the draft genome is shown with N’s inserted for gaps. Raw data was mapped back to the draft genome reference and depicted as a coverage plot. Finally, the BLASTx results are shown along with a short summary of each region covered and the percent identity and percent positive similarity.
  • the S segment encoding the nucleocapsid, has a consensus of 646/839 nt for 77% coverage.
  • the average coverage depth is 24X. Note that upon the last mapping of raw data, the missing 3’ region which is mostly 3’UTR can likely be extended.
  • the novel bunyavirus described herein was cloned into a pBluescript II XR predigested vector to synthesize a positive control for bunyavirus detection.
  • the linearized RNA is shown in FIG. 5.
  • Positive Control The primers and probes were first tested for the positive control sample (FIG. 5).
  • FIG. 6A shows detection of the L-segment/RdRp.
  • FIG. 6 A shows rt-PCR amplification curves using one in-vitro transcript (BUABTRD - transcript for the L- segment/RdRp) and set ofRdRp-FAM primers/probe in each reaction. Amplification curves shown are from FAM signals.
  • Bunyavirus RdRp Forward Primer ACCAGTAGCAAGTCCTGTATTA (SEQ ID NO: 4)
  • Bunyavirus RdRp Reverse Primer TTGCTATCTTACACTTCCTCTG (SEQ ID NO:
  • Bunyavirus RdRp Probe TGGCTGCTTTGAACTCTTGGAAATCACC (SEQ ID NO: TGGCTGCTTTGAACTCTTGGAAATCACC (SEQ ID NO: TGGCTGCTTTGAACTCTTGGAAATCACC (SEQ ID NO: TGGCTGCTTTGAACTCTTGGAAATCACC (SEQ ID NO: TGGCTGCTTTGAACTCTTGGAAATCACC (SEQ ID NO: TGGCTGCTTTGAACTCTTGGAAATCACC (SEQ ID NO: TGGCTGCTTTGAACTCTTGGAAATCACC
  • the probe was tagged with FAM at the 5’ end and with BGQla-Q at the 3’ end.
  • FIG. 6B shows rtPCR detection of the bunyavirus positive control using two in-vitro transcripts (BUABTRD, the transcript for the L-segment/RdRp and BUABTNC, the transcript for the nucleocapsid), and two sets of primers/probes added (RdRp-FAM and nucieoeapsid-Cy5) in each reaction.
  • the primers for the RdRp are described above (SEQ ID NO: 4, SEQ ID NO: 5), as well as the probe (SEQ ID NO: 6).
  • the sequences of the primers/probe for the nucleocapsid were as follows:
  • Bunyavirus Nucleocapsid Forward Primer GCTTGGCCAACTCAGATTTAACA (SEQ ID NO: 7)
  • Bunyavirus Nucleocapsid Reverse Primer CTTTTCTTTCCACAGAGCAGCTT (SEQ ID NO: 8)
  • Bunyavirus Nucleocapsid Probe CCGCATCTCCATGTTTGACTATGTCCC (SEQ ID NO: 9). The probe was tagged with Cy5 at the 5’ end and BHQ2a-Q at the 3’ end. [0180] Amplification curves shown are for shown are from FAM signals only (i.e. RdRp signals).
  • FIG. 6C shows an overlay of the amplification curves from FIG. 6A and FIG. 6B.
  • Patient Sample The RdRp primers and probes described above were subsequently- tested using a sample obtained from patient 594 (FIG. 7A-7C).
  • the RdRp primers SEQ ID NO: 4, SEQ ID NO: 5
  • probe SEQ ID NO: 6
  • Results for patient 594 compared to the previously obtained results using the positive control sample are shown in FIG. 7 A.
  • Amplification curves are for FAM signals. As shown in FIG. 7 A, the ct is roughly the same for the positive control and patient samples.
  • FIG. 7C shows an overlay of the results generated in FIG 7 A and 7B.
  • FIG. 9 A shows detection of the S-segment/nucleocapsid.
  • FIG. 9A shows rt-PCR amplification curves using one in-vitro transcript (BUABTNC, the transcript for the nucleocapsid) and set of nuc3eocapsid-Cy5 primers (SEQ ID NO: 7, SEQ ID NO: 8) and the nucleocapsid probe (SEQ ID NO: 9) in each reaction.
  • the probe was tagged with Cy5 at the 5' end and BHQ2a-Q at the 3’ end.
  • Amplification curves shown are from Cy5 signals.
  • FIG. 9B shows rtPCR detection of the bunyavirus positive control using two in-vitro transcripts (BUABTRD, the transcript for the L- segment/RdRp and BUABTNC, the transcript for the nucleocapsid), and two sets of primers/probe added (RdRp-FAM and nucleocapsid-Cy5) in each reaction.
  • the sequences of the primers/probe for nucleocapsid are described above (SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9).
  • RdRp primers SEQ ID NO: 4, SEQ ID NO: 5
  • probe SEQ ID NO: 6
  • the probe was tagged with FAM at the 5’ end and with BGQ1 a-Q at the 3 ’ end.
  • Amplification curves for FIG. 9B are from Cy5 signals only (i.e. nueleocapsid signals).
  • FIG. 9C shows a combination of the amplification curves from FIG. 9 A and FIG. 9B.
  • Patient Sample The nucleocapsid primers and probes were subsequently tested using a sample obtained from patient 594 (FIG. 10A-10C). The nucleocapsid primers (SEQ ID NO: 7, SEQ ID NO: 8) and probe (SEQ ID NO: 9) rvere used. Results for patient 594 compared to the previously obtained results using the positive control sample are shown in FIG. 10A. Amplification curves are for Cy5 signals. As shown in FIG. 10A, the ct is roughly the same for the positive control and patient samples.
  • nucleocapsid primers 2he ability for the nucleocapsid primers to properly amplify the desired segment in the presence of the RdRp primers and probes described above was also tested using the sample obtained from patient 594.
  • the nucleocapsid primers SEQ ID NO: 7, SEQ ID NO: 8) and probe (SEQ ID NO: 9) were used in combination with the RdRp primers (SEQ ID NO: 4, SEQ ID NO: 5) and probe (SEQ ID NO: 6). Results for Cy5 signals are shown in FIG. 10B,
  • FIG. 10C shows an overlay of the results generated in FIG. 10A and 10B.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des compositions, des procédés et des kits d'amplification et de détection des bunyavirus humains. Dans certains modes de réalisation, l'invention concerne des sondes et des amorces d'acide nucléique spécifiques de bunyavirus, et des procédés de détection d'acide nucléique de bunyavirus.
PCT/US2020/067314 2019-12-30 2020-12-29 Compositions et procédés pour la détection du bunyavirus WO2021138325A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962955082P 2019-12-30 2019-12-30
US62/955,082 2019-12-30

Publications (1)

Publication Number Publication Date
WO2021138325A1 true WO2021138325A1 (fr) 2021-07-08

Family

ID=74495015

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/067314 WO2021138325A1 (fr) 2019-12-30 2020-12-29 Compositions et procédés pour la détection du bunyavirus

Country Status (1)

Country Link
WO (1) WO2021138325A1 (fr)

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5118801A (en) 1988-09-30 1992-06-02 The Public Health Research Institute Nucleic acid process containing improved molecular switch
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
EP0500224A2 (fr) 1991-01-31 1992-08-26 Becton, Dickinson and Company Amplification par déplacement des brins à médiation exonucléase
US5185439A (en) 1987-10-05 1993-02-09 Gen-Probe Incorporated Acridinium ester labelling and purification of nucleotide probes
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5310652A (en) 1986-08-22 1994-05-10 Hoffman-La Roche Inc. Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US5399491A (en) 1989-07-11 1995-03-21 Gen-Probe Incorporated Nucleic acid sequence amplification methods
US5487792A (en) 1994-06-13 1996-01-30 Midwest Research Institute Molecular assemblies as protective barriers and adhesion promotion interlayer
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5846726A (en) 1997-05-13 1998-12-08 Becton, Dickinson And Company Detection of nucleic acids by fluorescence quenching
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US6235504B1 (en) 1999-01-11 2001-05-22 The Rockefeller University Methods for identifying genomic equivalent markers and their use in quantitating cells and polynucleotide sequences therein
US6277581B1 (en) 1999-03-01 2001-08-21 Lankenau Medical Research Center ODC allelic analysis method for assessing carcinogenic susceptibility
WO2001086001A1 (fr) 2000-05-09 2001-11-15 Biosearch Technologies, Inc. Extincteurs non-phosphorescents pour transfert d'energie donneur-accepteur
CN102409109B (zh) * 2011-11-25 2013-01-23 浙江省疾病预防控制中心 新型布尼亚病毒荧光定量检测试剂盒及该病毒的检测方法
WO2019025776A1 (fr) * 2017-07-31 2019-02-07 The Secretary Of State For Health Dosage de diagnostic de nairovirus

Patent Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683202B1 (fr) 1985-03-28 1990-11-27 Cetus Corp
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683195B1 (fr) 1986-01-30 1990-11-27 Cetus Corp
US5310652A (en) 1986-08-22 1994-05-10 Hoffman-La Roche Inc. Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5185439A (en) 1987-10-05 1993-02-09 Gen-Probe Incorporated Acridinium ester labelling and purification of nucleotide probes
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5312728A (en) 1988-09-30 1994-05-17 Public Health Research Institute Of The City Of New York, Inc. Assays and kits incorporating nucleic acid probes containing improved molecular switch
US5118801A (en) 1988-09-30 1992-06-02 The Public Health Research Institute Nucleic acid process containing improved molecular switch
US5399491A (en) 1989-07-11 1995-03-21 Gen-Probe Incorporated Nucleic acid sequence amplification methods
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US5804375A (en) 1990-08-06 1998-09-08 Roche Molecular Systems, Inc. Reaction mixtures for detection of target nucleic acids
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US6214979B1 (en) 1990-08-06 2001-04-10 Roche Molecular Systems Homogeneous assay system
EP0500224A2 (fr) 1991-01-31 1992-08-26 Becton, Dickinson and Company Amplification par déplacement des brins à médiation exonucléase
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5487792A (en) 1994-06-13 1996-01-30 Midwest Research Institute Molecular assemblies as protective barriers and adhesion promotion interlayer
US5846726A (en) 1997-05-13 1998-12-08 Becton, Dickinson And Company Detection of nucleic acids by fluorescence quenching
US6235504B1 (en) 1999-01-11 2001-05-22 The Rockefeller University Methods for identifying genomic equivalent markers and their use in quantitating cells and polynucleotide sequences therein
US6277581B1 (en) 1999-03-01 2001-08-21 Lankenau Medical Research Center ODC allelic analysis method for assessing carcinogenic susceptibility
WO2001086001A1 (fr) 2000-05-09 2001-11-15 Biosearch Technologies, Inc. Extincteurs non-phosphorescents pour transfert d'energie donneur-accepteur
CN102409109B (zh) * 2011-11-25 2013-01-23 浙江省疾病预防控制中心 新型布尼亚病毒荧光定量检测试剂盒及该病毒的检测方法
WO2019025776A1 (fr) * 2017-07-31 2019-02-07 The Secretary Of State For Health Dosage de diagnostic de nairovirus

Non-Patent Citations (54)

* Cited by examiner, † Cited by third party
Title
A. H. HOPMAN ET AL., EXP. CELL RES., vol. 169, 1987, pages 357 - 368
ANDRAS ET AL., MOL. BIOTECHNOL., vol. 19, 2001, pages 29 - 44
ANONYMOUS: "Replicase - Nyangole orthobunyavirus", 5 December 2018 (2018-12-05), XP055790035, Retrieved from the Internet <URL:https://www.uniprot.org/uniprot/A0A386BXX6> [retrieved on 20210325] *
BAYER ET AL., METHODS OF BIOCHEM. ANALYSIS, vol. 26, 1980, pages 1 - 45
BELOUSOV ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3440 - 3444
BERRY ET AL., CHN. CHEM., vol. 34, 1988, pages 2087 - 2090
BRIGATI ET AL., VIROL, vol. 126, 1983, pages 32 - 50
BROKER ET AL., NUCL. ACIDS RES., vol. 5, 1978, pages 363 - 384
BROWN ET AL., METH. ENZYMOL., vol. 68, 1979, pages 109 - 151
CONNOLY ET AL., NUCL. ACIDS. RES., vol. 13, 1985, pages 4485 - 4502
DATABASE EMBL [online] 1 August 2007 (2007-08-01), "Gryllus bimaculatus mRNA, GBcontig12201.", XP055789631, retrieved from EBI accession no. EM_HTC:AK265340 Database accession no. AK265340 *
DATABASE EMBL [online] 10 July 2020 (2020-07-10), "Bangui Virus segment L, complete sequence.", XP055790072, retrieved from EBI accession no. EM_STD:MK896632 Database accession no. MK896632 *
DATABASE EMBL [online] 20 December 2018 (2018-12-20), "Triniti virus strain TVRL7994 polyprotein gene, complete cds.", XP055789953, retrieved from EBI accession no. EM_STD:MG792214 Database accession no. MG792214 *
DATABASE EMBL [online] 4 October 2018 (2018-10-04), "Nyangole orthobunyavirus isolate E0-202 nucleocapsid protein gene, partial cds.", XP055789958, retrieved from EBI accession no. EM_STD:MH685709 Database accession no. MH685709 *
DATABASE EMBL [online] 4 October 2018 (2018-10-04), "Nyangole orthobunyavirus isolate E0-202 RNA-dependent RNA polymerase gene, partial cds.", XP055789939, retrieved from EBI accession no. EM_STD:MH685711 Database accession no. MH685711 *
DATABASE Geneseq [online] 1 November 2019 (2019-11-01), "JP 2019516393-A/7605: OLIGONUCLEOTIDE PROBES AND USES THEREOF.", XP055789949, retrieved from EBI accession no. EM_PAT:MB205406 Database accession no. MB205406 *
DATABASE Geneseq [online] 25 March 2003 (2003-03-25), "Human Rse rPTK probe.", XP055789692, retrieved from EBI accession no. GSN:AAQ94427 Database accession no. AAQ94427 *
DATABASE GS_NUC [online] SPLICINGCODES.COM: "US2017009304.151758", XP055789715, Database accession no. US2017009304.151758 *
FAHY ET AL., PCR METHODS AND APPLICATIONS, vol. 1, 1991, pages 25 - 33
GIACHETTI ET AL., J. CLIN. MICROBIOL, vol. 40, 2002, pages 2408 - 2419
GLUZMAN, CELL, vol. 23, 1981, pages 175
GUATELLI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 1874 - 1848
HOLLAND ET AL., PROC. NATL. ACAD. SCI., vol. 88, 1991, pages 7276 - 7280
I. WILSON, CELL, vol. 37, 1984, pages 767
JOOS ET AL., J. BIOTECHNOL., vol. 35, 1994, pages 135 - 153
KIEVITS ET AL., J. VIROL. METHODS, vol. 35, 1991, pages 273 - 286
KIMMEL, METHODS ENZYMOL, vol. 152, 1987, pages 307 - 316
KOSTRIKIS ET AL., SCIENCE, vol. 279, 1998, pages 1228 - 1229
KWOH ET AL., PROC. NATL. ACAD. SCL, vol. 86, 1989, pages 1173 - 1177
KYTE ET AL., J. MOL. BIOL., vol. 157, 1982, pages 105 - 132
L. J. KRICKA, ANN. CLIN. BIOCHEM., vol. 39, 2002, pages 114 - 129
LANDEGENT ET AL., EXP. CELL RES., vol. 15, 1984, pages 61 - 72
LANGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 78, 1981, pages 6633 - 6637
MANSFIELD ET AL., CELL. PROBES, vol. 9, 1995, pages 145 - 156
MARRAS ET AL., GENET. ANAL, vol. 14, 1999, pages 151 - 156
MCFARLAND ET AL., NUCLEIC ACIDS RES., vol. 7, 1979, pages 1067 - 1080
NARANG ET AL., METH. ENZYMOL, vol. 68, 1979, pages 90 - 98
PEARSON ET AL., J. CHROM., vol. 255, 1983, pages 137 - 149
PRICE ET AL., J. BIOL CHEM., vol. 244, 1969, pages 917
RICHARDSON ET AL., NUCL. ACIDS RES., vol. 11, 1983, pages 6167 - 6184
RP HAUGLAND: "The Handbook of Fluorescent Probes and Research Chemicals", June 1992, MOLECULAR PROBES, INC.
SAIKI: "Nature", vol. 324, 1986, pages: 163
SAMBROOK ET AL.: "Hybridization with Nucleic Acid Probes- Laboratory Techniques in Biochemistry and Molecular Biology (Parts I and II", 1993, COLD SPRING HARBOUR LABORATORY PRESS
SMITH ET AL., NUCL. ACIDS RES., vol. 13, 1985, pages 2399 - 2412
SOKOL ET AL., PROC. NATL ACAD. SCI. USA, vol. 95, 1998, pages 11538 - 11543
SOKOL, PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 11538 - 11543
TCHEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 3466 - 3470
TEMSAMANI ET AL., MOL. BIOTECHNOL., vol. 5, 1996, pages 223 - 232
TYAGI ET AL., NATURE BIOTECHNOL, vol. 16, 1998, pages 49 - 53
TYAGI ET AL., NATURE BIOTECHNOL., vol. 14, 1996, pages 303 - 308
VAN GIJLSWIJK ET AL., EXPERT REV. MOL. DIAGN., vol. 1, 2001, pages 81 - 91
WALKER ET AL., PNAS, vol. 89, 1992, pages 392 - 396
WEEKS ET AL., CHN. CHEM., vol. 29, 1983, pages 1474 - 1479
YULAN SUN ET AL: "Early diagnosis of novel SFTS bunyavirus infection by quantitative real-time RT-PCR assay", JOURNAL OF CLINICAL VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 53, no. 1, 29 September 2011 (2011-09-29), pages 48 - 53, XP028391939, ISSN: 1386-6532, [retrieved on 20111005], DOI: 10.1016/J.JCV.2011.09.031 *

Similar Documents

Publication Publication Date Title
US10689685B2 (en) Primers and probes for detecting human papillomavirus and human beta globin sequences in test samples
US7790386B2 (en) Neisseria gonorrhoeae specific oligonucleotide sequences
BRPI0708534A2 (pt) ensaio molecular para prognosticar a recorrência de cáncer do cólon dukes b
EP1945818B1 (fr) Séquences d&#39;oligonucléotides specifiques à chlamydia trachomatis
US20100255482A1 (en) Hepatitis B Virus (HBV) Specific Oligonucleotide Sequences
JP2012513757A (ja) Ｃ型肝炎ウイルスの検出用プライマー及びプローブ
WO2021138325A1 (fr) Compositions et procédés pour la détection du bunyavirus
US20230227924A1 (en) Compositions and methods for detecting picobirnavirus
US20150141287A1 (en) Genetic markers associated with intellectual disability
CN103160576A (zh) 基于SAA1β/β纯合子基因型的肝硬化预后诊断和/或肝硬化诊断的检测方法
JP2004008030A (ja) 脂質代謝異常の診断用プライマー並びに新規中鎖脂肪酸アシル−ＣｏＡ合成酵素およびその遺伝子

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20848906

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20848906

Country of ref document: EP

Kind code of ref document: A1